// App-Quantinova.ai

P106 : Feasibility Study of Methotrexate use Improvement in Rheumatoid Arthritis using Biomarker Feedback: The MIRA Trial

Researchers

Presenter

  • James Bluett

Principal Investigators

  • Kimme L Hyrich

  • Brian Keevil

  • Patty Doran

  • Anne Barton

Medical Centers

  • NIHR Manchester BRC, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom

  • The Faculty of Life Science, the University of Manchester, Manchester, United Kingdom

  • NIHR Manchester Musculoskeletal BioMedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom

  • NIHR Manchester Biomedical Research Centre, Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom

  • Versus Arthritis Centre for Genetics and Genomics, Centre for Musculoskeletal Research, University of Manchester, Manchester, UNITED KINGDOM

  • Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, University of Manchester, Manchester, UK, Manchester, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Methotrexate

Outcome

  • N/A

Study Design

  • Randomized

  • Multicenteric

  • Prospective

  • Controlled

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved